目的 评估小分子靶向药物安罗替尼与抗细胞程序性死亡蛋白-1(programmed death 1,PD-1)抑制剂替雷丽珠单抗联合治疗头颈部肿瘤患者的安全性和有效性.方法 回顾性选取2018年1月～2021年9月于北京肿瘤医院头颈外科接受PADF(洛铂+氟尿嘧啶+安罗替尼+替雷丽珠单抗)方案治疗的32例头颈部肿瘤患者作为观察组,另选取同期接受DF(洛铂+氟尿嘧啶)方案治疗的23例头颈部肿瘤患者作为对照组.以不良事件发生率评价联合治疗的安全性和耐受性,以肿瘤反应和患者生存期评价临床疗效.结果 观察组患者中,完全缓解1例(3.1％),部分缓解14例(43.8％),疾病稳定15例(46.9％),总缓解率为46.9％,疾病控制率为93.8％;7例(21.9％)发生3～4级不良事件.未观察到意外的不良事件或显著增加的毒性.结论 替雷丽珠单抗联合安罗替尼比传统化疗方案洛铂+氟尿嘧啶有更高的缓解率.
Abstract
Objective To evaluate the safety and efficacy of small molecule targeted drug anlotinib combined with anti-PD-1 in-hibitor tislelizumab in the treatment of patients with head and neck cancer.Methods A total of 32 patients with head and neck cancer who received PADF regimen(loplatin+fluorouracil+anlotinib+tislelizumab)in the Department of Head and Neck Surgery,Beijing Cancer Hospital from January 2018 to September 2021 were retrospectively selected as the observation group,and 23 patients with head and neck cancer who received DF regimen(loplatin+fluorouracil)during the same period were selected as the control group.The safety and tolerability of the combination therapy were evaluated by the incidence of adverse events,and the clinical efficacy was evaluated by tumor response and patient survival.Results In the observation group,1 patient(3.1％)had complete response,14 patients(43.8％)had partial response,15 patients(46.9％)had stable disease,total response rate and disease control rate were 46.9％and 93.8％,respectively.Grade 3-4 adverse events occurred in 7 patients(21.9％).No unexpected adverse events or significantly in-creased toxicity were observed.Conclusion Tislelizumab combined with anlotinib has a higher response rate than traditional chemothera-py DF.
关键词
替雷丽珠单抗/安罗替尼/头颈部肿瘤/临床疗效/安全性评价
Key words
Eislelizumab/Anlotinib/Head and neck cancer/Clinical efficacy/Safety evaluation
维普
万方数据